Gyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low – Here’s What Happened

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $5.87 and last traded at $5.94, with a volume of 125877 shares changing hands. The stock had previously closed at $6.06.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Zacks Research cut Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Finally, Weiss Ratings cut Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Stock Performance

The firm has a market capitalization of $576.36 million, a PE ratio of -65.99 and a beta of 2.03. The company has a fifty day simple moving average of $7.18 and a two-hundred day simple moving average of $7.58.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $37.20 million during the quarter, compared to the consensus estimate of $36.30 million. Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%. On average, equities analysts anticipate that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Gyre Therapeutics

In other news, CEO Ying Luo sold 10,136 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total value of $81,493.44. Following the completion of the transaction, the chief executive officer directly owned 2,565,226 shares of the company’s stock, valued at approximately $20,624,417.04. The trade was a 0.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Weiguo Ye sold 12,820 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total value of $78,843.00. Following the completion of the transaction, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at approximately $4,305,000. The trade was a 1.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 32,535 shares of company stock valued at $219,580. Corporate insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after acquiring an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. increased its position in Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Gyre Therapeutics during the 4th quarter valued at about $77,000. Finally, Wells Fargo & Company MN increased its position in Gyre Therapeutics by 132.4% during the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after buying an additional 7,361 shares in the last quarter. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.